Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure

Heart Failure Reviews

Volumn 10, Issue 1, 2005, Pages 71-78

  Zannad, Faiez ^a   Radauceanu, Anca ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Aldosterone; Cardiac extracellular matrix; Fibrosis; Heart failure; Remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; OSTEOPONTIN; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SCLEROPROTEIN; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CLINICAL TRIAL; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HORMONE ACTION; HORMONE INHIBITION; HUMAN; LOW DRUG DOSE; MORTALITY; PREDICTION; PROGNOSIS; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUDDEN DEATH; TISSUE REPAIR;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; COLLAGEN; EXTRACELLULAR MATRIX; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ALDOSTERONE; RENIN-ANGIOTENSIN SYSTEM;

EID: 21244431940     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-005-2351-3     Document Type: Article

References (56)

1. Weber K. Cardiac interstitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol 1989;13:1637-1652. 1:STN:280:BiaB2Mnjs1Q%3D
2. Butt RP, Laurent GJ, Bishop JE. Collagen production and replication by cardiac fibrobalsts is enhanced in response to diverse classes of growth factors. Eur J Cell Biol 1995;68:330-335. 1:CAS:528:DyaK28Xis1Knuw%3D%3D
3. Zhou G, Kandala JC, Tyagi SC, et al. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 1996;154:171-178. 1:CAS:528:DyaK28XhtVyrsr8%3D
4. Funck RC, Wilke A, Rupp H, et al. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997;432:35-44. 1:CAS:528:DyaK1cXivFejsro%3D
5. Chua CC, Hamdy RC, Cha BH. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochim Biophys Acta 1996;1311:175-180. 1:CAS:528:DyaK28XjtFartrw%3D
6. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 1997;26:101-111.
7. Pauschinger M, Knopf D, Petschauer S, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999;99:2750-2756. 1:STN:280:DyaK1M3otVCltQ%3D%3D
8. Kawamoto RM, Suzuki G, Morita H, et al. Matrix metalloproteinase 2 and 9 activity is increased in dogs with progressive left ventricular failure. Circulation 2001;104:II-738.
9. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530. 1:CAS:528:DC%2BD38XisFSks74%3D
10. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-1715. 1:STN:280:DyaK1c3lt1Cguw%3D%3D
11. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999;100:87-95. 1:STN:280:DyaK1Mzit1Cltw%3D%3D
12. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002;54:361-379. 1:CAS:528:DC%2BD38XivF2qsLY%3D
13. Xu J, Cui G, Esmailian F, et al. Atrial Extracellular Matrix Remodeling and the Maintenance of Atrial Fibrillation. Circulation 2004;109:363-368. 1:CAS:528:DC%2BD2cXks1CisQ%3D%3D
14. Mukherjee D, Sen S. Alteration of cardiac collagen phenotypes in hypertension hypertrophy: Role of blood pressure. J Mol Cell Cardiol 1993;25:185-196. 1:CAS:528:DyaK3sXitlWntb0%3D
15. Mukherjee D, Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest 1991;88:1141-1146. 1:CAS:528:DyaK3MXmsFeitL8%3D
16. Rhaleb N, Peng H, Harding P, et al. Effect of N-acetyl-seryl-aspartyl-lysyl proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 2001;37:827-832. 1:CAS:528:DC%2BD3MXitFegt7Y%3D
17. Sakata Y, Kazuhiro Y, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats. Its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004;109:2143-2149. 1:CAS:528:DC%2BD2cXjsVWru7s%3D
18. Brilla CG, Funck RC, Rupp H. Lisinopril mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-1393. 1:CAS:528:DC%2BD3cXntFKksbY%3D
19. Laviades C, Mayor G, Diez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens 1994;7:52-58. 1:STN:280:ByuC1czltVE%3D
20. Varo N, Iraburu MJ, Varela M, et al. Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000;35:1197-11202. 1:CAS:528:DC%2BD3cXksVCnsbY%3D
21. Pathak M, Sarkar S, Vellaichamy E, et al. Role of myocytes in myocardial collagen production. Hypertension 2001;37:833-840. 1:CAS:528:DC%2BD3MXitFegt7c%3D
22. Yamamoto K, Masuyama T, Sakata Y, et al. Myocardial stiffness is determined by ventricular fibrosis but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovascular Research 2002;55:76-82. 1:CAS:528:DC%2BD38XksVSit70%3D
23. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-2035. 1:CAS:528:DC%2BD2cXksVCjtL8%3D
24. Rizvi MA, Katwa L, Spadone DP, et al. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol 1996;28:243-252. 1:CAS:528:DyaK28Xht1ems7Y%3D
25. Mulder P, Boujedaini J, Richard V, et al. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation 2000;102:491-493. 1:CAS:528:DC%2BD3cXlvFKhur8%3D
26. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation 1997;96:2488-2892. 1:CAS:528:DyaK2sXnt1Kltbc%3D
27. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure. Interfering the aldosterone cardiac extracellular matrix relationship. Hypertension 2001;38:1227-1232. 1:CAS:528:DC%2BD3MXovVOrt7c%3D
28. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000;102:2700-2706. 1:STN:280:DC%2BD3M%2FmtVyntQ%3D%3D
29. Uusimaa P, Risteli J, Niemela M, et al. Collagen scar formation after acute myocardial infarction: Relationships to infarct size left ventricular function and coronary artery patency. Circulation 1997;96:2565-2572. 1:CAS:528:DyaK2sXnt1KksLk%3D
30. Host NB, Jensen LT, Bendixen PM, et al. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 1995;76:869-873. 1:STN:280:BymD2c7oslE%3D
31. Poulsen S, Host N, Jensen S, et al. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000;101:1527-1532. 1:CAS:528:DC%2BD3cXivVyhsbY%3D
32. Manhenke C, Orn S, Zannad F, et al. Elevated levels of serum of C-terminal telopeptide of type I collagen (ICTP) are associated with increased mortality in patients following complicated acute myocardial infarction. Circulation 2003;108:689.
33. Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995;75:913-918. 1:STN:280:ByqB2M%2Fms1w%3D
34. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-77. 1:CAS:528:DC%2BD3MXhtFemurw%3D
35. Brilla CG, Weber KT. Mineralocorticoid excess dietary sodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901. 1:CAS:528:DyaK3sXjslShug%3D%3D
36. Rocha R, Stier CT, Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878. 1:CAS:528:DC%2BD3cXmvVGmtrk%3D
37. Lijnen P, Petrov V. Antagonism of the Renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Clin Pharmacol 1999;21:215-227. 1:CAS:528:DyaK1MXktVeiurw%3D
38. Delcayre C, Silvestre J. Aldosterone and the heart: Towards a physiological function? Cardiovasc Res 1999;43:7-12. 1:CAS:528:DyaK1MXktVGltbY%3D
39. Brilla CG, Maisch B, Weber K. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: In vivo and in vitro studies on collagen matrix regulation. Clin Invest 1993;71:S35-S41. 1:CAS:528:DyaK2MXntlE%3D
40. Rudolph A, Rocha R, McMahon EG. Aldosterone target organ protection by eplerenone. Molecular and Cellular Endocrinology 2004;217:229-238. 1:CAS:528:DC%2BD2cXjvVequ7k%3D
41. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-677. 1:CAS:528:DyaK38XmsV2gtLc%3D
42. Brilla CG, Matsubara LS, Weber K. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A. 1:CAS:528:DyaK3sXhs1Srs7g%3D
43. Lacolley P, Safar M, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-667. 1:CAS:528:DC%2BD3MXhsl2jurg%3D
44. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62:723-731. 1:CAS:528:DC%2BD38XktF2ks7s%3D
45. Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiontensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002;143:4828-4836. 1:CAS:528:DC%2BD38Xpt1eltLs%3D
46. Fletcher GF, Murphy P. Cardiac procedures in acute care situations. Med Clin North Am 1981 65 67-81. 1:STN:280:Bi6C2cjjt1Q%3D
47. Ketelslegers J, Zannad F, Schriffrin E, et al. The effect of eplerenone on the cytokine osteopontin in post-MI heart failure: An EPHESUS substudy. Eur Heart J 2004;25:2912.
48. Wang D, Liu YH, Yan XP, et al. Role of a selective aldosterone blocker in mice with chronic heart failure following myocardial infarction. Circulation 2002;106:505.
49. Bauersachs J, Fraccarollo D, Schafer A, et al. Improvement fo ventricular remodeling in rats with CHF: Comparative and combined effect of aldosterone receptor blockade and angiotensin-converting enzyme inhibition. Eur Heart J 2002;23:401.
50. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone a novel aldosterone blocker on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-2972. 10.1161/01.CIR.0000039104.56479.42
51. Zannad F, Angiotensin-converting enzyme inhibitor and spironolactone combinaison therapy: New objectives in congestive heart failure treatment. Am J Cardiol 1993;71:34A-39A. 1:STN:280:ByyC3srhtlA%3D
52. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717. 10.1056/NEJM199909023411001
53. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovascular Research 1997;35:30-34. 1:CAS:528:DyaK2sXlvFejt74%3D
54. Hayashi M, Takayoshi T, Wada A, et al. Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction. Circulation 2003;107:2559-2565. 1:CAS:528:DC%2BD3sXjslehtLY%3D
55. Pitt B, Remme WJ, Zannad F, et al. A clinical trial of eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 2003;348:1309-1321. 1:CAS:528:DC%2BD3sXis1ehurY%3D
56. Zannad F, Ketelslegers J, Schiffrin EL, et al. The effect of eplerenone on markers of cardiac fibrosis: Insights from EPHESUS. JACC 2004;200A.